About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

As previously reported, Wedbush analyst Robert Driscoll downgraded Arvinas (ARVN) to Neutral from Outperform with a price target of $12, down from $57, after the company reported topline VERITAC-2 ...

– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq ...

--Arvinas, Inc. and Pfizer Inc. today announced positive topline results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen ...

Arvinas, Inc., a clinical-stage biotechnology company, and Pfizer Inc. announced detailed results from the phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus ...

Arvinas, Inc. (ARVN) shares soared 9.2% in the last trading session to close at $32.73. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant ...

The Phase 3 VERITAC-2 clinical trial (NCT05654623) is a global randomized study evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients ...

- Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial - NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) ...

News provided by Arvinas Inc. Apr 23, 2025, 10:44 AM ET – Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial – ...